Yoshimi, Akihide
Trippett, Tanya M.
Zhang, Nan
Chen, Xueyan
Penson, Alexander V.
Arcila, Maria E.
Pichardo, Janine
Baik, Jeeyeon
Sigler, Allison
Harada, Hironori
Fajgenbaum, David C.
Dogan, Ahmet
Abdel-Wahab, Omar
Xiao, Wenbin
Funding for this research was provided by:
Castleman Awareness and Research Effort/Castleman Disease Collaborative Network
Lauri Strauss Leukemia Foundation
Leukemia and Lymphoma Society
MEXT | Japan Society for the Promotion of Science
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL128239)
Starr Foundation (I8-A8-075)
Edward P. Evans Foundation
Leukemia and Lymphoma Society
Pershing Square Foundation
Article History
Received: 9 November 2019
Revised: 20 January 2020
Accepted: 30 January 2020
First Online: 12 February 2020
Compliance with ethical standards
:
: DCF receives research funding from EUSA Pharma for the ACCELERATE Registry (formerly sponsored by Janssen Pharmaceuticals). AD has received personal fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, and Novartis and research grants from National Cancer Institute, Roche. OA-W has served as a consultant for H3 Biomedicine, Foundation Medicine Inc., Merck, and Janssen and serves on the scientific advisory board of Envisagenics Inc.; OA-W has received personal speaking fees from Daiichi Sankyo. OA-W has received prior research funding from H3 Biomedicine unrelated to the current paper. OA-W is an inventor on a provisional patent application submitted by Fred Hutchinson Cancer Research Center that covers BRD9 activation in cancer. WX has received research support from Stemline therapeutics. Other authors have nothing to disclose.